News
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
CUPERTINO, Calif., Sept. 04, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024
CUPERTINO, Calif., Aug. 27, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules
CUPERTINO, Calif., Aug. 21, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 - - Registrational RECOVER-2 trial in schizophrenia expected to initiate Q3 2024; topline data expected Q4 2025 - - European patent granted covering brilaroxazine use for treating pulmonary...
Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis
CUPERTINO, Calif., Aug. 06, 2024 -- -Similar patent has also been granted in Japan -Brilaroxazine has received Orphan Drug Designation for the treatment of idiopathic pulmonary fibrosis (IPF) Cupertino, Calif., August 6, 2024 - Reviva Pharmaceuticals Holdings, Inc....
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Similar patents have...
Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CUPERTINO, Calif., May 29, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CUPERTINO, Calif., May 28, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva to Participate in the BIO International Convention
CUPERTINO, Calif., May 21, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
- 358 enrolled and 223 patients currently on treatment across sites in the USA, Europe and Asia - - Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia - - Topline data from 1-year open-label extension (OLE) trial expected...